Advertisement


Arlene O. Siefker-Radtke, MD, on Metastatic Urothelial Carcinoma: New Data on Erdafitinib and Cetrelimab From the NORSE Study

2023 ASCO Annual Meeting

Advertisement

Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, discusses the combination of erdafitinib and cetrelimab, which demonstrated clinically meaningful activity and was well tolerated in cisplatin-ineligible patients with metastatic urothelial carcinoma and fibroblast growth factor receptor alterations (Abstract 4504).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Arlene O. Siefker-Radtke: The NORSE clinical trial was designed to study erdafitinib and erdafitinib in combination with cetrelimab in the frontline treatment of patients with metastatic urothelial tumors. The premise behind this trial was that the FGF-altered tumor, which has been associated with an immunologically cold tumor microenvironment, may benefit from the combination of erdafitinib with cetrelimab, a checkpoint inhibitor that targets PD-1 expression found on tumor. This clinical trial was a randomized, yet non-comparative cohort trial similar to what has been used with other clinical trials in this space. Approximately 45 patients were randomized in each arm, erdafitinib only, and erdafitinib plus cetrelimab. Patients must have been ineligible for cisplatin-based chemotherapy and not received prior treatment for their urothelial carcinoma. When we look at the results, erdafitinib only had an objective response rate that was around 45%, similar to what has been reported on other clinical trials of erdafitinib in the second-line space. The combination of erdafitinib plus cetrelimab was associated with an objective response rate of around 55%, with a trend toward more and deeper responses, regardless of PD-L1 expression levels that were observed in the tumor tissue. We also saw benefit in progression-free survival with erdafitinib having a 5.5 month progression-free survival similar to second-line strategies and the combination of erdafitinib with cetrelimab having a progression-free survival of around 11 months. This translated to an overall survival of 16 months with erdafitinib only, and the combination of erdafitinib with cetrelimab had a median overall survival of 20.8 months, which is similar to other targeted strategies in the frontline cisplatin-ineligible space. So, as a result of this trial, we see evidence of efficacy and benefit with erdafitinib in the single-agent space. We also see a potential for benefit with combination therapy that's worth further study. Not only did we see an improvement in overall survival that was statistically significant, we also saw an improvement in progression-free survival with erdafitinib coming in at 5.5 months, and single-agent chemotherapy having a progression free survival rate that was half that amount. This also translated to an improved objective response rate. Erdafitinib had an objective response rate of 45% compared to 11% observed with single-agent taxane. So, erdafitinib showed evidence of clinical benefit by objective responses, progression-free survival, and median overall survival in the treatment of urothelial carcinoma. The toxicity profile was also quite similar to what has been observed with other FGF-targeted strategies with hyperphosphatemia, hand-foot syndrome, and mucositis as being the most frequent toxicities. We saw Central serous retinopathy in approximately 20% of patients, and this was with use of screening, with baseline screening with an ophthalmology exam and optical coherence tomography testing at baseline, and monthly, for the first four months. So, in all, erdafitinib is here to stay with improved benefit, improved response rate, progression-free survival, and overall survival, providing hope for the longevity of our bladder cancer patients with metastatic urothelial tumors.

Related Videos

Kidney Cancer

Rana R. McKay, MD, and Toni K. Choueiri, MD, on RCC: New Findings on Efficacy and Safety of Atezolizumab Plus Cabozantinib

Rana R. McKay, MD, of the University of California, San Diego, and Toni K. Choueiri, MD, of Dana-Farber Cancer Institute and Harvard Medical School, discuss results from the phase III CONTACT-03 study, showing that, for patients with metastatic renal cell carcinoma (RCC), adding the PD-L1 inhibitor atezolizumab to cabozantinib did not improve clinical outcomes compared with treatment with cabozantinib alone. In addition, higher toxicities were observed in the combination arm (Abstract LBA4500).

Lung Cancer

Narjust Florez, MD, and Ticiana Leal, MD, on Metastatic NSCLC: Tumor Treating Fields Therapy After Platinum Resistance

Narjust Florez, MD, of Dana-Farber Cancer Institute, and Ticiana Leal, MD, of Winship Cancer Institute of Emory University, discuss the use of tumor treating fields therapy, in which electric fields disrupt processes critical for cancer cell viability. Already approved by the FDA to treat glioblastoma and mesothelioma, the treatment has extended overall survival in this phase III study of patients with metastatic non–small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, without exacerbating systemic toxicities (Abstract LBA9005).

Gynecologic Cancers

Bobbie J. Rimel, MD, and Kathleen N. Moore, MD, on Ovarian Cancer: New Findings on Mirvetuximab Soravtansine vs Chemotherapy

Bobbie J. Rimel, MD, of Cedars-Sinai Medical Center, and Kathleen N. Moore, MD, of the Stephenson Oklahoma Cancer Center at the University of Oklahoma, discuss phase III results from the MIRASOL trial, which showed that mirvetuximab soravtansine-gynx prolonged overall survival vs investigator’s choice chemotherapy in patients with platinum-resistant ovarian cancer with high folate receptor-alpha expression. The findings suggest a new standard of care for this disease (Abstract LBA5507).

Lymphoma

Muhit Özcan, MD, on DLBCL: Now Recruiting Previously Untreated Patients for a Study of Zilovertamab Vedotin Plus Chemotherapy

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses waveLINE-007, a two-part study now recruiting in more than 20 locations, to determine the safety and recommended phase II dose of the antibody-drug conjugate zilovertamab vedotin in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL). Efficacy of this regimen will be investigated in the second half of the study (Abstract TPS7589).

Myelodysplastic Syndromes

Amer Methqal Zeidan, MBBS, MHS, on Myelodysplastic Syndromes: New Data From the IMerge Study of Imetelstat

Amer Methqal Zeidan, MBBS, MHS, of Yale University and Yale Cancer Center, discusses phase III findings on the first-in-class telomerase inhibitor imetelstat, which was given to patients with heavily transfusion-dependent non-del(5q) lower-risk myelodysplastic syndromes that are resistant to erythropoiesis-stimulating agents. Imetelstat resulted in a significant and sustained red blood cell (RBC) transfusion independence in 40% of these heavily transfused patients. The response was also durable and accompanied by an impressive median hemoglobin rise of 3.6 g/dL, and seen in patients with and without ring sideroblasts. Importantly, reduced variant allele frequency was observed in the most commonly mutated myeloid genes which correlated with duration of transfusion independence and hemoglobin rise, therefore suggesting a disease-modifying potential of this agent (Abstract 7004).

Advertisement

Advertisement




Advertisement